• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Mesa Nilda converted options into 650 shares, increasing direct ownership by 13% to 5,678 units (SEC Form 4)

    7/13/26 4:36:12 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UTHR alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Mesa Nilda

    (Last)(First)(Middle)
    C/O UNITED THERAPEUTICS CORPORATION
    1000 SPRING STREET

    (Street)
    SILVER SPRING MARYLAND 20910

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    UNITED THERAPEUTICS Corp [ UTHR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    07/09/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock07/09/2026M(1)650A$0.00(1)5,678D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Restricted Stock Units$0.00(1)07/09/2026M(1)65007/09/2026 (2)Common Stock650$0.00(1)0.00D
    Explanation of Responses:
    1. Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock.
    2. Not applicable as restricted stock units do not have an expiration date.
    Remarks:
    /s/ John S. Hess, Jr. under Power of Attorney07/13/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $UTHR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UTHR

    DatePrice TargetRatingAnalyst
    5/7/2026$735.00Equal Weight → Overweight
    Wells Fargo
    4/10/2026$700.00Outperform
    Raymond James
    10/20/2025$414.00Underweight
    Wells Fargo
    9/26/2025$569.00Outperform
    RBC Capital Mkts
    6/2/2025$405.00Overweight
    Cantor Fitzgerald
    4/25/2025Overweight → Equal Weight
    Wells Fargo
    4/21/2025$314.00Underperform → Neutral
    BofA Securities
    7/11/2024$310.00 → $321.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $UTHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $5,051,035 worth of shares (9,500 units at $531.69) as part of a pre-agreed trading plan (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    7/21/26 4:35:35 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $5,101,939 worth of shares (9,500 units at $537.05) as part of a pre-agreed trading plan (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    7/20/26 4:32:21 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $5,043,689 worth of shares (9,500 units at $530.91) as part of a pre-agreed trading plan (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    7/17/26 4:30:25 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BETA Technologies and Multistate Collaborative Complete First Operational Flights of the U.S. DOT and FAA's eVTOL Integration Pilot Program

    The flights carried manufactured organs, being developed by United Therapeutics The flights are also the first in a series of use cases that will touch at least 26 states nationwide BETA Technologies, Inc. (BETA) (NYSE:BETA), an aerospace and defense company, and the Multistate Collaborative eIPP National Integration Complex today announced the completion of the first electric conventional takeoff and landing ("CTOL") aircraft flights conducted under the U.S. Department of Transportation ("U.S. DOT") and the Federal Aviation Administration ("FAA")’s eVTOL Integration Pilot Program ("eIPP"), the federal government's new initiative to evaluate how Advanced Air Mobility ("AAM") aircraft ca

    7/10/26 12:35:00 PM ET
    $BETA
    $UTHR
    Aerospace
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation Acquires Thymmune Therapeutics

    United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the immune system, including training T-cells, which are essential for fighting infections and other diseases. Thymmune has a proprietary process for converting human-induced pluripotent stem cells (iPSC) into thymic cells, which — once inside the body — mature into c

    7/2/26 6:30:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion

    LungFX™ is the first device approved for centralized ex vivo lung perfusion for donor organs not otherwise used for transplant, an important step in advancing United Therapeutics’ platforms United Therapeutics Corporation (NASDAQ:UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of the LungFXTM device (LungFX) for use in centralized ex vivo lung perfusion (EVLP), a procedure that enables donor lungs to be assessed outside the body after procurement and before transplantation. The PMA, submitted by United Therapeutics’ wholly owned subsidiary, Lung Bioengineering Inc., included comprehensive safety a

    6/29/26 6:30:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    SEC Filings

    View All

    SEC Form S-8 POS filed by United Therapeutics Corporation

    S-8 POS - UNITED THERAPEUTICS Corp (0001082554) (Filer)

    7/13/26 6:41:43 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by United Therapeutics Corporation

    S-8 POS - UNITED THERAPEUTICS Corp (0001082554) (Filer)

    7/13/26 6:40:53 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by United Therapeutics Corporation

    S-8 POS - UNITED THERAPEUTICS Corp (0001082554) (Filer)

    7/13/26 6:39:26 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $146.03 and sold $4,579,018 worth of shares (8,000 units at $572.38) as part of a pre-agreed trading plan (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    5/27/26 4:30:25 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    United Therapeutics upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded United Therapeutics from Equal Weight to Overweight and set a new price target of $735.00

    5/7/26 8:00:38 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on United Therapeutics with a new price target

    Raymond James initiated coverage of United Therapeutics with a rating of Outperform and set a new price target of $700.00

    4/10/26 8:35:42 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on United Therapeutics with a new price target

    Wells Fargo initiated coverage of United Therapeutics with a rating of Underweight and set a new price target of $414.00

    10/20/25 8:04:30 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Financials

    Live finance-specific insights

    View All

    United Therapeutics Corporation Acquires Thymmune Therapeutics

    United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the immune system, including training T-cells, which are essential for fighting infections and other diseases. Thymmune has a proprietary process for converting human-induced pluripotent stem cells (iPSC) into thymic cells, which — once inside the body — mature into c

    7/2/26 6:30:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation Reports First Quarter 2026 Financial Results

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2026. Total revenues in the first quarter of 2026 decreased by two percent year-over-year to $781.5 million, compared to $794.4 million in the first quarter of 2025. "In the first quarter of 2026, we extended our run of clinical success, with positive results from both our ADVANCE OUTCOMES and TETON-1 studies," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "These readouts have the potential to meaningfully expand the breadth of our future growth and support further revenue diversification while

    5/6/26 6:30:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2026 financial results in a press release that will be issued on Wednesday, May 6, 2026 at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast on Wednesday, May 6, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. About United Therapeutics Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics tran

    4/22/26 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Leadership Updates

    Live Leadership Updates

    View All

    United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Kevin J. Tracey, M.D., to its Board on January 21, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122174254/en/Kevin Tracey was recently elected to United Therapeutics' Board of Directors. Dr. Tracey is President, CEO, and the Karches Family Distinguished Chair in Medical Research at The Feinstein Institutes for Medical Research. He is a Professor of Molecular Medicine and Neurosurgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Executive Vice Pres

    1/22/26 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors

    WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the

    1/27/21 8:00:00 AM ET
    $CLGN
    $UTHR
    $XERS
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $UTHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by United Therapeutics Corporation

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    11/8/24 4:30:29 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by United Therapeutics Corporation

    SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    10/16/24 1:03:48 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    6/10/24 12:15:17 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care